Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.52 |
| ▸ | MEN1 | O00255 | 4/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 3/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5682090 | 0.84 | OPRM1 (0.50) | KMT2AMEN1SMN1; SMN2OPRM1NPSR1 | |
| SCHEMBL9238358 | 0.80 | TDP1 (0.45) | KMT2AMEN1SMN1; SMN2OPRM1CYP3A4 | |
| SCHEMBL28840766 | 0.79 | ALDH1A1 (0.43) | KMT2AMEN1SMN1; SMN2OPRM1NPSR1 | |
| SCHEMBL5682238 | 0.78 | SMN1; SMN2 (0.51) | KMT2AMEN1SMN1; SMN2OPRM1NPSR1 | |
| SCHEMBL1976788 | 0.78 | SMN1; SMN2 (0.55) | KMT2AMEN1SMN1; SMN2OPRM1HTT | |
| SCHEMBL5495720 | 0.77 | CNR2 (0.39) | KMT2AMEN1SMN1; SMN2OPRM1NPSR1 | |
| SCHEMBL5353712 | 0.77 | OPRM1 (0.36) | KMT2AMEN1SMN1; SMN2OPRM1CYP2C19 | |
| SCHEMBL9768195 | 0.77 | ABCB11 (0.54) | KMT2AMEN1OPRM1GAACYP1A2 | |
| SCHEMBL9416717 | 0.77 | MEN1 (0.48) | KMT2AMEN1SMN1; SMN2OPRM1HTT | |
| Methylamine SCHEMBL9416751 | 0.76 | SLC6A4 (0.48) | KMT2AMEN1SMN1; SMN2OPRM1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9447038-B2 | Substituted B-amino acid derivatives as CXCR3 receptor antagonists | SANOFI (FR) | 2016-09-20 | — | — | US | disclosed |
| US-9447038-B2 | Substituted B-amino acid derivatives as CXCR3 receptor antagonists | SANOFI (FR) | 2016-09-20 | — | — | US | disclosed |
| EP-2852578-B1 | SUBSTITUTED ß-AMINO ACID DERIVATIVES AS CXCR3 RECEPTOR ANTAGONISTS | SANOFI SA (FR) | 2016-04-27 | — | — | EP | disclosed |
| US-20150073004-A1 | SUBSTITUTED B-AMINO ACID DERIVATIVES AS CXCR3 RECEPTOR ANTAGONISTS | SANOFI (FR) | 2015-03-12 | — | — | US | disclosed |
| US-20150073004-A1 | SUBSTITUTED B-AMINO ACID DERIVATIVES AS CXCR3 RECEPTOR ANTAGONISTS | SANOFI (FR) | 2015-03-12 | — | — | US | disclosed |
| WO-2013174485-A1 | SUBSTITUTED ß-AMINO ACID DERIVATIVES AS CXCR3 RECEPTOR ANTAGONISTS | SANOFI (FR) | 2013-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150073004-A1 | SUBSTITUTED B-AMINO ACID DERIVATIVES AS CXCR3 RECEPTOR ANTAGONISTS | CXCR3, CXCR1, CXCR2 | KMT2A 4399/4885MEN1 4459/4885SMN1; SMN2 4741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.